收费全文 | 105407篇 |
免费 | 8874篇 |
国内免费 | 323篇 |
耳鼻咽喉 | 1065篇 |
儿科学 | 3119篇 |
妇产科学 | 2814篇 |
基础医学 | 15203篇 |
口腔科学 | 2085篇 |
临床医学 | 11952篇 |
内科学 | 20644篇 |
皮肤病学 | 1735篇 |
神经病学 | 10696篇 |
特种医学 | 3488篇 |
外国民族医学 | 1篇 |
外科学 | 11522篇 |
综合类 | 1335篇 |
现状与发展 | 1篇 |
一般理论 | 91篇 |
预防医学 | 11939篇 |
眼科学 | 1902篇 |
药学 | 7238篇 |
2篇 | |
中国医学 | 180篇 |
肿瘤学 | 7592篇 |
2023年 | 897篇 |
2022年 | 1381篇 |
2021年 | 3487篇 |
2020年 | 2051篇 |
2019年 | 2987篇 |
2018年 | 3350篇 |
2017年 | 2404篇 |
2016年 | 2569篇 |
2015年 | 2780篇 |
2014年 | 3546篇 |
2013年 | 4768篇 |
2012年 | 7351篇 |
2011年 | 7461篇 |
2010年 | 3880篇 |
2009年 | 3314篇 |
2008年 | 5501篇 |
2007年 | 5678篇 |
2006年 | 5448篇 |
2005年 | 5211篇 |
2004年 | 4687篇 |
2003年 | 4232篇 |
2002年 | 3896篇 |
2001年 | 1834篇 |
2000年 | 1874篇 |
1999年 | 1695篇 |
1998年 | 1020篇 |
1997年 | 801篇 |
1996年 | 740篇 |
1995年 | 709篇 |
1994年 | 572篇 |
1993年 | 568篇 |
1992年 | 1322篇 |
1991年 | 1229篇 |
1990年 | 1200篇 |
1989年 | 1125篇 |
1988年 | 1036篇 |
1987年 | 1027篇 |
1986年 | 951篇 |
1985年 | 943篇 |
1984年 | 758篇 |
1983年 | 674篇 |
1982年 | 472篇 |
1981年 | 432篇 |
1980年 | 431篇 |
1979年 | 677篇 |
1978年 | 534篇 |
1977年 | 430篇 |
1974年 | 455篇 |
1973年 | 446篇 |
1972年 | 454篇 |
Interstitial lung disease (ILD) represents a significant cause of morbidity and mortality in systemic sclerosis (SSc). The purpose of this study was to examine recirculating lymphocytes from SSc patients for potential biomarkers of interstitial lung disease (ILD). Peripheral blood mononuclear cells (PBMCs) were isolated from patients with SSc and healthy controls enrolled in the Vanderbilt University Myositis and Scleroderma Treatment Initiative Center cohort between 9/2017–6/2019. Clinical phenotyping was performed by chart abstraction. Immunophenotyping was performed using both mass cytometry and fluorescence cytometry combined with t-distributed stochastic neighbor embedding analysis and traditional biaxial gating. This study included 34 patients with SSc-ILD, 14 patients without SSc-ILD, and 25 healthy controls. CD21lo/neg cells are significantly increased in SSc-ILD but not in SSc without ILD (15.4 ± 13.3% vs. 5.8 ± 0.9%, p = 0.002) or healthy controls (5.0 ± 0.5%, p < 0.0001). While CD21lo/neg B cells can be identified from a single biaxial gate, tSNE analysis reveals that the biaxial gate is comprised of multiple distinct subsets, all of which are increased in SSc-ILD. CD21lo/neg cells in both healthy controls and SSc-ILD are predominantly tBET positive and do not have intracellular CD21. Immunohistochemistry staining demonstrated that CD21lo/neg B cells diffusely infiltrate the lung parenchyma of an SSc-ILD patient. Additional work is needed to validate this biomarker in larger cohorts and longitudinal studies and to understand the role of these cells in SSc-ILD.
相似文献Areas covered: We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research.
Expert opinion: All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited. 相似文献